Laurus Labs inks pact with MPP to produce molnupiravir
PTI, Jan 21, 2022, 11:46 AM IST
Image Source: Wikimedia
New Delhi: Drug firm Laurus Labs on Friday said it has inked a pact with Geneva-based MPP (Medicine Patient Pool) for manufacturing the oral COVID-19 antiviral medication molnupiravir.
”We are happy to sign an agreement to manufacture the oral COVID-19 anti-viral medication, which is an urgent need of the hour, this is one of the most critical step towards fighting the pandemic and we are happy to contribute to the mission,” Laurus Labs Founder and CEO Satyanarayana Chava said in a regulatory filing.
Molnupiravir is an orally administered ribonucleoside analog that inhibits the replication of SARS CoV2, and clinical studies have shown this drug to be active against the most common COVID-19 variants.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Sensex reclaims 80k mark; Nifty surges over 1% after BJP-led Mahayuti’s win in Maharashtra
Rapid digital expansion to create over 1 lakh new jobs in fiber tech in India in next 5 years
Choose correct ITR to report foreign assets; 2 lakh such returns filed: CBDT official
Air India Express increases flight operations from northeast destinations
Mcap of 8 of top-10 most-valued domestic firms jumps Rs 1.55 lakh cr; HDFC Bank, TCS sparkle
MUST WATCH
Latest Additions
Wanted to kill Ajmal Kasab who caused so much of pain, recalls 26/11 terror attack victim
Two retired revenue officials among four arrested in land grabbing case in Jammu
Kerala govt to revise manual for junior doctors, house surgeons
State can interfere with religious practices if they impede development, equality rights: SC
Four cheers at MP’s Kuno park; cheetah Neerva gives birth to cub quartet
Thanks for visiting Udayavani
You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.